Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

NCT01813136 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Carcinoma

Interventions

DRUG: Continuous pazopanib (Arm A)
DRUG: Intermittent pazopanib (Arm B)

Sponsor

Centre Leon Berard

Collaborators

[object Object]